Neurocrine Bioscineces, Inc. (NASDAQ:NBIX) Q1 2020 Earnings Conference Call May 6, 2020 4:30 PM ET Company Participants Kevin Gorman ??? Chief Executive Officer Todd Tushla ??? Head-Investor Relations Matt Abernethy ??? Chief Financial Officer Eric Benevich ??? Chief Commercial Officer Eiry Roberts ??? Chief Medical Officer Kyle Gano ??? Chief Business Development Officer Conference Call Participants Paul Matteis ??? Stifel Biren Amin ??? Jefferies LLC Jack Allen ??? Baird Anupam Rama ??? JPMorgan Jay Olsen ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q Washington, D.C. 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR 12780 El Camino Real, San Diego, California 92130 (Address of principal executive office) (Zip Code) (IRS Employer Identification No.) (858) 617-7600 (Registrant's telephone number, including area code) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANG ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Commission file number 0-22705 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 33-0525145 (State or other jurisdiction of incorporation or organization) 12780 El Camino Real, San Diego, California 92130 (Address of principal executive offices) (Zip Code) (858) 617-7600 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Co ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2019 Earnings Conference Call February 4, 2020 4:30 PM ET Company Participants Kevin Gorman - Chief Executive Officer Todd Tushla - Head of Investor Relations Eiry Roberts - Chief Medical Officer Eric Benevich - Chief Commercial Officer Matt Abernethy - Chief Financial Officer Kyle Gano - Head of to BD and Strategy Conference Call Participants Tazeen Ahmad - Bank of America Paul Matteis - Stifel Brian Skorney - Baird Owen Drinkwater - RBC Capital Markets Tessa R ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-22705 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 33-0525145 (State or other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-22705 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 33-0525145 (State or other juris ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-22705 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 33-0525145 (State or other juri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-22705 NEUROCRINE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporatio ...